The data are insufficient to support standardized treatment of all patients with frostbite with thrombolytic therapy. The following guidelines, however, should be applied to all patients with cyanosis persisting proximal to the distal phalanx (Grade 3 or 4 frostbite injury) and demonstrated loss of perfusion at or proximal to the middle phalanx immediately after rewarming.
The data are insufficient to support standardized treatment of all patients with frostbite with thrombolytic therapy. The following guidelines, however, should be applied to all patients with cyanosis persisting proximal to the distal phalanx (Grade 3 or 4 frostbite injury) and demonstrated loss of perfusion at or proximal to the middle phalanx immediately after rewarming.
RECOMMENDATIONS

Standards
The data are insufficient to support standardized treatment of all patients with frostbite with thrombolytic therapy. The following guidelines, however, should be applied to all patients with cyanosis persisting proximal to the distal phalanx (Grade 3 or 4 frostbite injury) and demonstrated loss of perfusion at or proximal to the proximal interphalangeal joint of a finger or toe, or the interphalangeal joint of the great toe or thumb immediately after rewarming.
Practice Guidelines
• Patients can be considered for treatment with thrombolytic therapy if there is clinical evidence of risk for soft tissue loss and treatment can be initiated within 48 hours from the initial cold exposure. • Patients with a loss of distal blood flow confirmed by loss of Doppler signals o and no contraindications to thrombolytic therapy should be emergently discussed with a burn center that specializes in frostbite care.
• Although rapid rewarming is essential for the management of both hypothermia and frostbite, consideration should be given to minimizing warm ischemia time for isolated areas of frostbite. Options for minimizing warm ischemia time may include delay of the rapid rewarming sequence (of the isolated area of frostbite involvement) or initiation of thrombolytic therapy prior to imaging -in coordination with a burn center that specializes in frostbite care. • Centers treating frostbite with thrombolytic therapy should document the clinical exam with photographs and recording of the distal extent of appreciable Doppler signal at the time of initiating rewarming, and at the initiation of thrombolytic therapy and then, again, at a delayed interval. • Thrombolytic therapy can be administered in accordance with local hospital protocols. Examples include use in cases of ischemic stroke or myocardial infarction. There is no clear advantage to intravenous versus intraarterial routes of administration. Preference should be given to the protocol that will allow for the shortest time from diagnosis to thrombolytic treatment. • In addition to efforts to quantitate the most proximal extent of injury, centers should collect measures of estimated total time of cold exposure, warm ischemia time (estimated to begin at time rapid rewarming is started), and door-to-thrombolysis time. These metrics not only serve as quality measures but also will facilitate comparison of results in future publications. • Centers treating frostbite with thrombolytic therapy should assess tissue salvage with photographs and measures of estimated grade of frostbite -at admission (after rewarming) and 3-7 days after admission. Use of a universal scoring system such as the Hennepin score would greatly facilitate reporting and comparison of results. Follow-up data should include ultimate level of amputation (if applicable), amount of residual pain, and degree of disability.
Options
• Rapid rewarming, without the use of thrombolytic, may offer chance of recovery; however, the rewarming should be completed with the understanding that the tissue survival time during warm ischemia is markedly shorter than during the period of cold ischemia time. • Administration of pentoxifylline (to decrease blood viscosity and improve microcirculation). • Administration of nonsteroidal anti-inflammatory medications (aspirin and/or ibuprofen). • Anticoagulation therapy in conjunction with, and after, thrombolytic administration. Strategies include: Initial intravenous heparin with a therapeutic goal of up to twice the partial thromboplastin time control, enoxaparin sodium at therapeutic doses, and oral anticoagulation (warfarin). • Iloprost, a stable metabolite of prostaglandin I2 (PGI 2 , Prostacyclin).
OVERVIEW
Purpose
The purpose of this guideline is to review the evidence supporting the use of intravascular delivery (both intravenous (IV) and intraarterial [IA]) of tissue plasminogen activator (t-PA) as an adjunct to decreasing soft tissue loss after frostbite of the extremity and offer insight into helpful metrics that future clinical reviews and prospective studies could incorporate to further our understanding of this injury process.
Users
These guidelines are intended to aid burn physicians and emergency medical team members in decision making regarding the appropriate use of thrombolytic therapy in the treatment of frostbite. It is important that team members along the continuum of care are aware of the options, guidelines, and regional practice patterns to facilitate prompt interventions and successful outcomes.
Process
The American Burn Association Organization and Delivery of Burn Care Committee (ODBC) appreciates the increased frequency of reports of the use of tPA in the treatment of frostbite. This care is frequently delivered at burn centers in the United States. There is some disparity between the use of IV versus IA therapy and the ideal conditions as well as expected outcome. Using a previously outlined process, a working group was assembled. 1 The working group was composed of committee members as well as American Burn Association members with a demonstrated interest or with recent experience with tPA use in the management of frostbite. Specifically, the group reviewed the available evidence supporting the efficacy of intravascular tPA in the treatment of frostbite patients. After a literature search, a guideline draft was submitted to the entire committee for review and then to experts in the field. These stakeholders were identified based on their record of publication at multiple time points -as a reflection of ongoing interest in the topic.
Search Strategy
In order to ensure initial inclusion of all potentially informative articles for review, a PubMed search was conducted in December of 2016 using the keyword frostbite ( Figure 1) . A second PubMed search was conducted, in January of 2018, again using the keyword frostbite. The titles of 2191 articles were reviewed for initial relevancy to efficacy of thrombolytic therapy and human studies. From this initial group, 52 articles were identified for review. The titles of literature cited in these articles were also reviewed for possible inclusion, as well as referenced articles.
Selection for Inclusion
Independent reviewers (SH, KB, LJ, AW, RF) assessed each of the 52 articles for inclusion. Only full-length primary articles were included. Articles were restricted to case series (no case reports with reviews). The title and the abstract were scrutinized, and 15 articles were then included for the full review process.
Data Extraction and Analysis
As described by Law et al, each of the 15 articles was reviewed by, at least, two reviewers. 2 The review process utilizes a scoring system, which critiques the individual elements of study purpose, literature review, study sample, outcomes, interventions, results, conclusions, and clinical implications. The reviewers calculated a total score as the sum from each element. The totals were compared and differences were considered minor if the scores were ±2 points of one another. These minor differences were discussed to arrive at consensus. Table 1 summarizes the scores for the 15 articles. Table 2 summarizes the characteristics of the included studies. 
RESULTS
Study Characteristics
Scientific Foundation
The use of thrombolytic therapy began with experimental work reported by Salimi et al. 3 The authors appreciated the potential to mitigate injury by shortening the period of ischemia subsequent to macrovascular thrombosis. The first human trial was completed at the Hennepin County Burn Center. 4 Between December 1985 and 1989, 16 patients were evaluated with Tc-99 MDP triple-phase bone scans and served as historic controls. Between January 1, 1989, and February 1, 2003, 13 additional patients were treated in an open label study. Six were treated with IA tPA. From 1995 to 1997, IV dosing was optimized on 7 patients followed by 6 final patients between 1997 and 2003 who were treated with the optimized IV dosing regimen. In the control group, those with no perfusion (or minimal perfusion distal to the cutoff on delayed images) all of these patients ultimately needed amputations. They found that 16 of the 19 study patients responded to thrombolysis with amputations occurring in 33 of 174 (19%) affected digits. They noted only two complications with therapy and these were in patients receiving IA therapy. Bruen et al reported their retrospective experience with the use of only IA thrombolysis. 5 Between 2001 and 2006, patients identified with "circulation compromise" and no contraindications to tPA were evaluated by digital angiography. Tissue plasminogen activator was administered for no more than 48 hours. Seven patients were treated, with 6 patients reaching treatment within 24 hours of exposure. Amputation was required in 6 of 59 affected digits (10%) versus 49 of 120 (41%) in the control group.
At about the same time, Cauchy et al briefly reported their 12-year experience treating 47 patients in a prospective study in which patients were randomized into one of three groups: 1) aspirin and buflomedil, 2) aspirin and prostacyclin, and 3) aspirin and IA iloprost and recombinant IA tPA. 6 Treatment effectiveness was evaluated at 8 days postinjury. The risk of amputation for the first group was 60% versus 0% in the second and 19% in the third group.
A follow-up report of the Hennepin County Burn Center experience was composed of a second cohort of patients with frostbite. 7 Using the IV protocol reported by Twomey et al, the charts of 11 additional patients from 2008 to 2010 were reviewed. Patients were included if they had no improvement with rewarming, and signs of significant vascular embarrassment by Doppler exam or Tc-99m 3-phase bone scanning. In addition, patients were required to have less than 24 hours of warm ischemia time. In this study, 59% of digits at risk were amputated.
The 2015 report of 3 cases by Ibrahim et al reported their success with IA tPA. 8 Beginning in 2012, patients with decreased vascular inflow and impending tissue necrosis were taken for emergent diagnostic angiography. They reported a 100% salvage rate and no complications.
The largest series of IA thrombolytic therapy was published in 2016 by Gonzaga et al. 9 The study was of a retrospective cohort design and examined patients admitted from 1990 to 2007. Of 114 patients, 69 underwent angiography. Sixty-four of these patients were found to have complete data after having undergone IA thrombolytic therapy. The amputation rate was 31%. The group was able to examine population subgroups and found that if no digital flow could be reestablished and the amputation rate was 95%. If partial vascular flow was reestablished, the amputation rate was 37%.
A number of studies were published in 2017 regarding the use of thrombolytic therapy in the treatment of frostbite. Tavri et al reported a series of 13 patients treated with catheterdirected thrombolysis. 10 This was a retrospective examination of 13 patients accumulated from 2009 until 2015. Initially, 82% digits that were treated showed no distal flow past the metacarpophalangeal or the metatarsophalangeal joints. The amputation rate was 17%.
Patel et al reported their experience with 8 patients treated with IA thrombolysis. 11 There was a 15% rate of amputation. Patients with contraindications to tPA served as the control group and had an amputation rate of 77%.
Intra-arterial infusion was also used as the primary treatment after angiography as part of the Helsinki frostbite management protocol. 12 Severe injury, defined as clinical ischemic signs at or proximal to the proximal interphalangeal joint of the thumb or multiple affected digits, was identified in 14 patients with 10 patients obtaining angiography. Of the 10 patients undergoing angiography, 9 underwent treatment with tPA, 3 patients were treated with IA iloprost alone, and 2 patients received neither medication. The digital salvage rate was 75% with 81% soft tissue salvage by the Hennepin score.
Wexler and Zavala shared their experience with IV infusion of tPA in a series of 6 patients. The amount of injury was retrospectively graded, and the endpoint was the need for amputation. 13 They reported a digital salvage rate of 25% despite thrombolytic therapy. Patients were offered treatment based solely at the discretion of the admitting physician.
Jones et al reported the experience of a burn center using IV tPA. 14 In their series, the need for therapy and effectiveness of therapy were assessed by Tc-99m scanning. Of 9 patients undergoing nucleotide testing, 7 went on to tPA with 5 patients requiring partial amputations.
The importance of time to intervention of thrombolytic therapy was addressed by a follow-up series from Hennepin County Burn Center. 15 They note that patients with frostbite injury have population characteristics that make it difficult to control the exposure interval -the time at which the injury occurs to the time the patient presents to a treatment facility. However, their study observed that of the 45 patients who received tPA therapy, the time between rewarming and thrombolytic therapy was longer in patients who required amputation. Using the Hennepin score, they demonstrated that an additional 27% loss of tissue occurred with each hour delay.
DISCUSSION
As is the case of many issues in burn care, the individual reports include relatively low numbers of patients. The challenge of assessing any relative difference is increased by low numbers of patients, variable presentations, and management techniques and disparity of assessments/measures. However, the use of thrombolytic therapy would appear a logical approach to treatment of a disease process that leads to vascular thrombosis and decreased tissue perfusion. There is no clear advantage to either IV or IA delivery of tPA at this time.
Regarding the challenging topic of how to effectively assess the burden of tissue injury and potential of tissue salvage, Cauchy et al have the largest breadth of publications. 6, [16] [17] [18] Their work supports the relative importance of "grade" over "degree" in reporting severity of frostbite. 18 More recently, a novel quantification of tissue salvage has been proposed -the Hennepin score. 19 The time to treatment is an important quality metric in the treatment of frostbite. The work from Hennepin County Burn Center supports the notion that "time is tissue" similar to that of the treatment of ischemic stroke or myocardial infarction. 15 Cold ischemia time is probably less critical (and certainly less mutable by treating physicians) than warm ischemia time. Similar to cold ischemia time, the amount of frankly necrotic soft tissue present on admission can be estimated, but is not a factor that can be improved by clinicians. It is worth noting that cold ischemia is much better tolerated than warm ischemia by survival rates of amputated digits (another form of complete ischemia) that undergo replantation in a nonfrostbite setting. 20, 21 If the premise is accepted that warm ischemia time is more deleterious than cold ischemia time, then strategies to shorten warm ischemia time need to be considered. The critical period begins with warming of the affected tissues and ends with initiation of thrombolytic therapy. Possible strategies could include a center's preference for IV or IA therapy based on how rapidly studies and interventions can occur in the local setting. The concept of initiating tPA immediately after rapid rewarming, at a referring emergency department, may be applicable in some regions. Ultimately, this would require cooperation of referring facilities and accepting burn centers. For the sake of completeness, there may be some logic in purposeful delay of rewarming of isolated regions of frostbite in the emergency department to a secondary goal so as to reduce the burden of warm ischemia time. However, this option might still lead to passive rewarming and prolonged warm ischemia time.
It is likely that an increasing number of burn centers may begin to consider administration of thrombolytic therapy. If ischemia time is a paramount concern, then earlier administration of thrombolytics may be logical. However, given potential risks of managing frostbite outside of an experienced center, we strongly recommend the simultaneous collection of prospective of quality metrics. These would include: 1) estimate of time exposed to cold, 2) time of admission, 3) time of starting rewarming, 4) objective measure of tissue perfusion at about the time of administration of tPA (via Doppler examination of distal extent of flow in the extremity or digit or via radiographic study), 5) pictures prior to and after tPA administration, 6) time of first thrombolytic administration objective measure of tissue perfusion at about the time of administration (via Doppler examination of digital flow level, nuclear medicine, or angiographic measure), and 7) prospectively collected estimation of injury grade (or Hennepin score) at the time of admission and 3-7 days after admission.
